Various hypolipodemic agents are widely used in clinical settings to decrease low-density cholesterol (LDL) or triglyceride concentration in human plasma. Recently, several HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitors (HCRI) have been marketed. 1,2) The disadvantage of these drugs is the risk of myopathy in patients taking them. Unfortunately, there has been no quantitative method for evaluating their myopathy risk.We previously proposed a quick and convenient screening system for evaluating the risk of myopathy following a single oral administration of pravastatin (PV) as a representative HCRI alone or coadministration with bezafibrate (BF) by screening the creatine phosphokinase (CPK) level in rats.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.